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Apoptosis is a cell suicide programme characterised by unique cellular events such as mitochondrial fragmentation and dysfunction,
nuclear condensation, cytoplasmic shrinkage and activation of apoptotic protease caspases, and these serve as the noticeable
apoptotic markers for the commitment of cell demise. Here, we show that, however, the characterised apoptotic dying cancer cells
can regain their normal morphology and proliferate after removal of apoptotic inducers. In addition, we demonstrate that reversibility
of apoptosis occurs in various cancer cell lines, and in different apoptotic stimuli. Our findings show that cancer cells can survive after
initiation of apoptosis, thereby revealing an unexpected potential escape mechanism of cancer cells from chemotherapy.
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Chemotherapy is one of the major cancer treatments by promoting
cancer cells into different types of cell death including apoptosis
(Johnstone et al, 2002; Perona and Sa ´nchez-Pe ´rez, 2004; Brown
and Attardi, 2005; Li et al, 2008). Accumulating studies reported
that cancers initially retreated in response to chemotherapy, but
returned during repeated courses of treatment (Norton and Simon,
1977; Stephens and Peacock, 1977; Davis and Tannock, 2000; Wu
and Tannock, 2003; Kim and Tannock, 2005). Although the
mechanisms of the cancer recurrence are not well understood, it is
generally believed that repopulation of surviving cancer cells
during the intervals between treatments is an important cause of
the treatment failure (Kim and Tannock, 2005). The survival of
cancer cells during treatments has been mainly attributed into the
deficiency of apoptotic pathways in cancer cells (Letai, 2008),
anticancer drug resistance of tumorigenic stem cells (Dean et al,
2005), and inefficiency of drug penetration into solid tumours for
achieving a therapeutic effect (Minchinton and Tannock, 2006). In
this study, we found that cancer cells could survive even after
initiation of apoptosis, and this was observed in various cancer cell
lines and in different apoptotic stimuli. Our findings reveal
another possibility that may contribute into the cancer cell survival
during therapy, reversibility of apoptosis in cancer cells.
MATERIALS AND METHODS
Cell culture
Human cervical cancer HeLa cells, skin cancer A375, liver cancer
HepG2, breast cancer MCF7 cells (from American Type Culture
Collection) were cultured in DMEM (Dulbecco’s minimum
essential medium) supplemented with 10% heat-inactivated FBS
(fetal bovine serum), 100Uml
 1 penicillin and 100mgml
 1
streptomycin (Gibco, Carlsbad, CA, USA), at 371C under an
atmosphere of 5% CO2/95% air. Human prostate cancer PC3 cells
were cultured in the same condition with RPMI-1640 medium.
Cells were seeded on tissue culture plates until the cell
density reached 70% confluency before being subjected to
each experiment. Apoptotic stimuli jasplakinolide (Invitrogen,
Carlsbad, CA, USA), staurosporine (Sigma, St Louis, MO, USA)
and ethanol (Scharlau, Barcelona, Spain) were applied to the cells.
Living cell staining
Cells were grown to 70% confluence on a glass coverslip
(Marienfeld, Lauda-Ku ¨nigahofen, Germany). Mitochondria and
nucleuses were stained with 50nM MitoTracker Red CMXRos
(Invitrogen) and 250ngml
 1 Hoechst 33342 (Invitrogen), respec-
tively for 20min, and the cells were washed two times with PBS and
then cultured in suitable fresh medium (Invitrogen).
Real-time living cell microscopy
Cells were cultured in CO2-independent medium (Invitrogen)
on a thermo-cell culture FCS2 chamber (Bioptechs, Butler, PA,
USA) mounted onto the adapter in the stage of an inverted
fluorescence microscope Cell Observer (Carl Zeiss, Jena,
Germany). Cell morphology was visualised by differential inter-
ference contrast (DIC) microscope device, and the mitochondria
and nucleuses were by fluorescence with excitation 561 and
405nm, respectively. Drugs and culture medium were introduced
to the cell culture chamber through the perfusion tubes
(Bioptechs) connected to the cell chamber. Cell images were
captured with a monochromatic CoolSNAP FX camera (Roper
Scientific, Pleasanton, CA, USA) using a  63 numerical aperture
(NA) 1.4 Plan-Apochromat objective (Carl Zeiss), and analysed by
using AxioVision 4.2 software (Carl Zeiss).
Confocal microscopy
Confocal cell images were captured with an inverted laser-scanning
microscope LSM 5 LIVE (Carl Zeiss), with 1mm interval between
each focal plane. The images were analysed by using LSM image
examiner software (Carl Zeiss).
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sBiochemical and cell proliferation assays
One thousand cells were grown in a 96-well plate for 24h, and then
treated with different conditions. At each designed time point, cells
were subjected to the corresponding assays according to the
manufacturer’s instructions. The activity of effector caspases was
measured by using the homogeneous caspase assay kit (Roche,
Mannheim, Germany). The activity of mitochondria was measured
by 3-(4,5-dimethylthiazol-2-yl)-2,5 -diphenyltetrazolium bromide
(MTT) assay (Sigma). The cell survival was detected by the cell
proliferation ELISA BrdU assay kit (Roche). Results of assays were
measured by SpectraMax 250 microplate reader (Molecular
Devices Corp, Concord, ON, Canada).
Cell counting
The morphology of the cells was observed by DIC, whereas
mitochondria and nucleuses were visualised by fluorescence
microscopy. At least 100 cells were examined in at least three
independent cell counting.
For cell proliferation, at each indicated time point, the cells were
harvested by trypsinisation and thoroughly resuspended. The cells were
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iv. Induced
00:00 00:17 00:27
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02:31 03:00 04:03
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Figure 1 Time-lapse living cell microscopy of HeLa cells under and after jasplakinolide induction. Real-time imaging of the same cells before 0.5mM
jasplakinolide induction (Untreated, i), induced for 3h (Induced, ii–viii), and then washed and further incubated with fresh culture medium for another 14.5h
(Washed, ix–xii). Merged images: mitochondria (red) and nucleuses (blue) were visualised by fluorescence, and cell morphology was by DIC. Time
presented as hr:min. Scale bar: 10mm. A corresponding movie is available as the Supplementary Information (Video 1).
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with hemocytometer. Total cell number is calculated by multiplying the
determined cell density with the total volume of suspension.
Western blot analysis
Approximately 3mg protein per lane was separated on a 10%
SDS-PAGE gel and transferred onto a Hybond ECL
s membrane
(Amersham Biosciences, Chalfont St Giles, UK). After blocking, the
membrane was incubated overnight at 41C with 1:1000 anti-
caspase-3 antibody (Cell Signaling, Danvers, MA, USA) followed
by another hour of incubation in the corresponding horseradish
peroxidase-conjugated secondary antibody (Bio-Rad, Hercules,
CA, USA) at 1:5000 dilutions, and the signal was detected with the
ECL western blotting detection system (Amersham Biosciences).
RESULTS
Survival of HeLa cells from jasplakinolide-induced
apoptosis
Our aim was to induce cancer cells undergoing apoptosis, and
investigate whether the apoptotic dying cancer cells could survive
after the removal of apoptotic reagents. We initially exposed
Untreated
Induced
Washed
Figure 2 Confocal microscopy for verification on the morphological
alternation of HeLa cells during reversibility of apoptosis. Confocal imaging
of the HeLa cells before 0.5mM jasplakinolide induction (Untreated),
induced for 3h (Induced), and the induced cells washed and further
incubated with fresh culture medium for another 24h (Washed). Merged
images: mitochondria (red) and nucleuses (blue) were visualised by
fluorescence. Scale bar: 10mm.
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Figure 3 Caspases and mitochondria activity of HeLa cells in different
apoptotic stimuli. (A)( i) Caspases activity of the HeLa cells before the
0.5mM jasplakinolide induction (0h), induced for 3h (3h), and then washed
and cultured for 24h (W24h), 48h (W48h) and 72h (W72h). A
thousand of corresponding cells were subjected into caspases assay. The
degree of corresponding caspases activities were normalised with the
control. (ii) Western blot analysis of pro-caspase-3 and cleaved caspase-3
in the total cell lysate from the cells at 0, 3 and W24h. (B) Mitochondria
activity of the untreated HeLa cells before the 0.5mM jasplakinolide
induction (0h), induced for 3h (3h), and then washed and cultured for
24h (W24h), 72h (W48h) and 168h (W168h). (Mean±s.d.; *Po0.02;
n¼3). (C) Proliferation of the jasplakinolide-induced cells after removal of
inducer. HeLa cells were induced with 0.5mM jasplakinolide for 3h (3h),
then washed and further incubated in fresh medium for 24h (W24h), 48h
(W48h) and 72h (W72h).
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shuman cervical carcinoma HeLa cells to an apoptotic inducer
jasplakinolide (Odaka et al, 2000), and observed the change in the
cellular morphology by real-time living cell microscopy. Figures 1
and 2 show that, in untreated healthy cells, mitochondrial network
was extensively interconnected and appeared filamentous ex-
tended throughout cytoplasm, and the nucleus is in round shape,
as previous studies described (Kerr et al, 1972; Jacobson et al,
1997; Taylor et al, 2008). In a 3h-induction, as expected, the cells
displayed morphological landmarks of apoptosis-associated
mitochondrial fragmentation, perinuclear redistribution of
mitochondria, nuclear condensation and cytoplasmic shrinkage
(Figures 1 and 2). The initiation of apoptosis was further
confirmed by the biochemical landmarks of apoptosis (Wang,
2001), the activation of apoptotic protease caspases detected by
colorimetric caspases assay (Figure 3Ai), the cleavage of pro-
caspase-3 (Figure 3Aii) and also the dysfunction of mitochondria
by MTT assay (Figure 3B). Then, the apoptotic dying cells were
washed and further cultured in a fresh cell medium (the wash). It
has been generally assumed that cells displaying all these apoptotic
landmarks are determined to die (Kerr et al, 1972; Jacobson et al,
1997; Green and Kroemer, 2004; Taylor et al, 2008). Mitochondrial
destruction and activation of caspases have been known to indicate
irreversible cell death (Green and Kroemer, 2004; Riedl and Shi,
2004). Here, we reasoned that, if the apoptotic dying cells could
survive even after the activation of caspase-3, the cells should be
able to restore themselves and proliferate after the wash.
Interestingly, our results indicate that HeLa cells could actually
survive after the apoptotic induction. Our living cell microscopy
showed that the shrunk cells regained their normal cellular
morphology in 14.5h after the wash (Figure 1, and Supplementary
Video 1). Our confocal microscopy was performed to verify the
morphological recovery of the cells in 24h after removal of the
inducer (Figure 2). The cell counting results showed that 96% of
the cells displayed all the morphological landmarks of apoptosis in
a 3h-induction, whereas 92% of the cells regained their normal
morphology after the wash in 24h (Figure 4). Besides, the caspases
and mitochondria activity also returned back to the level of the
control cells in 72 and 168h after the wash, respectively (Figure 3A
and B). Furthermore, survival of the cells after the wash was
proven by cell proliferation. The result of cell count showed the
increase in the cell number after the removal of the inducer
(Figure 3C). The cell survival after reversal was further assessed by
the uptake of a DNA synthesis marker bromodexyuridine (BrdU)
(Figure 5A). The percentage of proliferation of the cells did not
significantly differ between the control and the 3h-induced cells
after the wash (Figure 5A). Our data shows that the morphological
and biochemical landmarks of apoptosis vanished in 24h after the
removal of the apoptotic jasplakinolide induction, and the induced
cells survived afterward. Noticeably, our time-course study in cell
count showed that the percentage of cells displaying nuclear
fragmentation increased along the continuous apoptotic induction,
and that was inversely proportional to the cell proliferation ability
after removal of the apoptotic reagent at that time point (Figures
5A and B). Perhaps nuclear fragmentation is the apoptotic
landmark event indicating the irreversible stage of apoptosis.
Reversibility of apoptosis in different inducers and in
various cancer cell lines
Our discovery on reversibility of jasplakinolide-induced apoptosis
in HeLa cells evoked a novel phenomenon that cancer cells could
survive after initiation of apoptosis, and therefore prompted us to
investigate whether this was a general phenomenon in different
apoptotic inductions and in various cancer cell lines. Our results
on other apoptotic stimuli to HeLa cells showed that, in response
to the induction of apoptotic inducers ethanol and staurosporine
(Bertrand et al, 1994; Young et al, 2003), HeLa cells underwent
apoptosis characterised by excessive mitochondrial fragmentation,
nuclear condensation and cell shrinkage (Figure 4). After removal
of the inducers, the indicated cells regained their normal
morphology in 24h in the culture of a fresh medium. In further
experiments, jasplakinolide was applied to various cancer cell
lines, which are widely used in cancer research including human
skin cancer A375, liver cancer HepG2, breast cancer MCF7 and
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Figure 4 Reversibility of apoptosis in HeLa cells in different apoptotic inductions. Percentage of cells showing mitochondrial fragmentation (Mito.
Fragment), nuclear condensation (Nuc. Condense), and cell shrinkage (Cell Shrink) of the control HeLa cells (Untreated), the cell treated with 0.5mM
jasplakinolide for 3h (Jasp.), 6% (v/v) ethanol for 30min (EtOH) or staurosporine for 1h (STS), and the corresponding cells washed and cultured with fresh
medium for 24h (Washed). (Mean±s.d.; *Po0.02; n¼3).
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Figure 5 Reversibility of apoptosis after different duration of jasplakino-
lide-induction. HeLa cells were treated with 0.5mM of jasplakinolide for 0,
3h, 1 day, 2 days, 3 days and 4 days. (A) Percentage of HeLa cell
proliferation (detected by BrdU assay) after removal of the inducer at the
indicated time and cultured for another 5 days in fresh medium. (B)
Percentage of corresponding cells showing nuclear fragmentation (detected
by fluorescence microscopy followed by cell counting) at the inducted time
before the removal of the inducer.
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sprostate cancer PC3 cells, and all of them displayed the morpho-
logical features of apoptosis (Figure 6). Consistently, after removal
of jasplakinolide, the morphological recovery was observed in 24h
in all the cell lines (Figure 6). These results suggest that the
reversibility of apoptosis is a general phenomenon in cancer cells.
DISCUSSION
In this study, we have shown that cancer cells could survive after
initiation of apoptosis induced by different stimuli, and the
reversibility of apoptosis was observed in various cancer cell lines.
We provided evidence that cancer cells could escape from demise
even after the cells undergoing critical apoptotic events such as
mitochondrial fragmentation and dysfunction, nuclear condensa-
tion, cell shrinkage and activation of caspases. Importantly, the
reversibility of apoptosis was abolished when the cells reached the
apoptotic event of nuclear fragmentation, suggesting that this is an
important cellular event indicating the point-of-no-return in
apoptosis.
Our discovery on the reversibility of apoptosis in cancer cells
lead to several unanswered key questions: what are the compo-
nents of the machinery driving the reversibility of apoptosis, and
how are they linked to the regulation of apoptosis in cancer cells
as a whole? To what extent does the reversibility of apoptosis
contribute to the survival and repopulation of cancer cells during
the cycles of anticancer treatment? Intriguingly, can inhibition on
the reversibility of apoptosis in cancer cells suppress cancer
relapse? Providing answers to these questions will be critical in
understanding the mechanism for regulation on the reversibility of
apoptosis, and provide us new potential targets for therapeutical
advancement to our war of cancer. A more in-depth analysis will
be required to clarify these points.
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